- New global cardiology guidelines issued by three organizations may give a jump to a struggling heart-failure drug from Novartis (NVS +1.5%).
- Experts from the American College of Cardiology, the American Heart Association and the European Society of Cardiology have agreed that Novartis' Entresto should replace old ACE inhibitors and ARBs, in patients with adequate blood pressure and drug tolerance.
- The groups also said Corlanor, from Amgen (AMGN +1%), may be beneficial when given on top of beta blockers for some heart failure patients.
- Despite a heavy buildup, first-quarter sales of Entresto were just $17M and Novartis sees only $200M in sales this year.
- Now read A New Realm Of Therapeutics Is Emerging: Johnson & Johnson And Novartis Are Key Players »